An update on the treatment of hypogonadism, Part 1: Hypergonadotropic hypogonadism

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

This review concentrates on the treatment for some of the more common causes of hypergonadotropic hypogonadism. Females with hypergonadotropic hypogonadism have constituted much of this data because those with chromosomally competent ovarian failure (CCOF) and chromosomally incompetent ovarian failure (CIOF) have the potential to conceive, and women with CIOF have been treated hormonally in attempts to increase growth. Males with chromosomally incompetent gonad failure (CIGF), most commonly 47,XXY, are not short, so this is not an issue. Pure 47,XXY males rarely are able to impregnate women unless they are mosaics. More data is needed in CIOF women before the final consensus of recombinant growth hormone (rGH) and oxandrolone can be reached. It is important to note that treatment with rGH has been restricted to study protocols, and only the treatment of growth hormone deficiency is FDA approved. Currently it appears prudent to discuss treatment options with patients having hypergonadotropic hypogonadism with respect to sexual development, reproductive potential, growth, and the prevention of complications such as osteoporosis and heart disease. It is the opinion of this author that if patients do desire to use rGH and oxandrolone, that they be treated by physicians directly involved in research protocols or after discussion with investigators who have experience in these treatment protocols. The induction of secondary sexual characteristics may be started after the completion of treatment for growth, which may be up to 3-5 years. If the woman does not desire therapy for growth, it appears reasonable to begin hormone replacement at ages 9-11, or at the time of diagnosis, if the individual is older. Likewise, males may begin testosterone treatment beginning at about ages 10-12. Support, discussion about potential complications of the disease and the replacement medication, and psychologic considerations must be considered for the complete management in individuals with hypogonadism.

Original languageEnglish (US)
Pages (from-to)183-193
Number of pages11
JournalAdolescent and Pediatric Gynecology
Volume7
Issue number4
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Hypogonadism
Growth Hormone
Oxandrolone
Clinical Protocols
Growth
Therapeutics
Sexual Development
Gonads
Osteoporosis
Testosterone
Heart Diseases
Research Personnel
Hormones
Physicians
Research

Keywords

  • Hypergonadotropic hypogonadism
  • Ovarian failure
  • Sexual development

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

An update on the treatment of hypogonadism, Part 1 : Hypergonadotropic hypogonadism. / Layman, Lawrence C.

In: Adolescent and Pediatric Gynecology, Vol. 7, No. 4, 01.01.1994, p. 183-193.

Research output: Contribution to journalReview article

@article{171ab89c816c48ff91af9928596e1c10,
title = "An update on the treatment of hypogonadism, Part 1: Hypergonadotropic hypogonadism",
abstract = "This review concentrates on the treatment for some of the more common causes of hypergonadotropic hypogonadism. Females with hypergonadotropic hypogonadism have constituted much of this data because those with chromosomally competent ovarian failure (CCOF) and chromosomally incompetent ovarian failure (CIOF) have the potential to conceive, and women with CIOF have been treated hormonally in attempts to increase growth. Males with chromosomally incompetent gonad failure (CIGF), most commonly 47,XXY, are not short, so this is not an issue. Pure 47,XXY males rarely are able to impregnate women unless they are mosaics. More data is needed in CIOF women before the final consensus of recombinant growth hormone (rGH) and oxandrolone can be reached. It is important to note that treatment with rGH has been restricted to study protocols, and only the treatment of growth hormone deficiency is FDA approved. Currently it appears prudent to discuss treatment options with patients having hypergonadotropic hypogonadism with respect to sexual development, reproductive potential, growth, and the prevention of complications such as osteoporosis and heart disease. It is the opinion of this author that if patients do desire to use rGH and oxandrolone, that they be treated by physicians directly involved in research protocols or after discussion with investigators who have experience in these treatment protocols. The induction of secondary sexual characteristics may be started after the completion of treatment for growth, which may be up to 3-5 years. If the woman does not desire therapy for growth, it appears reasonable to begin hormone replacement at ages 9-11, or at the time of diagnosis, if the individual is older. Likewise, males may begin testosterone treatment beginning at about ages 10-12. Support, discussion about potential complications of the disease and the replacement medication, and psychologic considerations must be considered for the complete management in individuals with hypogonadism.",
keywords = "Hypergonadotropic hypogonadism, Ovarian failure, Sexual development",
author = "Layman, {Lawrence C}",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/S0932-8610(19)80172-X",
language = "English (US)",
volume = "7",
pages = "183--193",
journal = "Journal of Pediatric and Adolescent Gynecology",
issn = "1083-3188",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - An update on the treatment of hypogonadism, Part 1

T2 - Hypergonadotropic hypogonadism

AU - Layman, Lawrence C

PY - 1994/1/1

Y1 - 1994/1/1

N2 - This review concentrates on the treatment for some of the more common causes of hypergonadotropic hypogonadism. Females with hypergonadotropic hypogonadism have constituted much of this data because those with chromosomally competent ovarian failure (CCOF) and chromosomally incompetent ovarian failure (CIOF) have the potential to conceive, and women with CIOF have been treated hormonally in attempts to increase growth. Males with chromosomally incompetent gonad failure (CIGF), most commonly 47,XXY, are not short, so this is not an issue. Pure 47,XXY males rarely are able to impregnate women unless they are mosaics. More data is needed in CIOF women before the final consensus of recombinant growth hormone (rGH) and oxandrolone can be reached. It is important to note that treatment with rGH has been restricted to study protocols, and only the treatment of growth hormone deficiency is FDA approved. Currently it appears prudent to discuss treatment options with patients having hypergonadotropic hypogonadism with respect to sexual development, reproductive potential, growth, and the prevention of complications such as osteoporosis and heart disease. It is the opinion of this author that if patients do desire to use rGH and oxandrolone, that they be treated by physicians directly involved in research protocols or after discussion with investigators who have experience in these treatment protocols. The induction of secondary sexual characteristics may be started after the completion of treatment for growth, which may be up to 3-5 years. If the woman does not desire therapy for growth, it appears reasonable to begin hormone replacement at ages 9-11, or at the time of diagnosis, if the individual is older. Likewise, males may begin testosterone treatment beginning at about ages 10-12. Support, discussion about potential complications of the disease and the replacement medication, and psychologic considerations must be considered for the complete management in individuals with hypogonadism.

AB - This review concentrates on the treatment for some of the more common causes of hypergonadotropic hypogonadism. Females with hypergonadotropic hypogonadism have constituted much of this data because those with chromosomally competent ovarian failure (CCOF) and chromosomally incompetent ovarian failure (CIOF) have the potential to conceive, and women with CIOF have been treated hormonally in attempts to increase growth. Males with chromosomally incompetent gonad failure (CIGF), most commonly 47,XXY, are not short, so this is not an issue. Pure 47,XXY males rarely are able to impregnate women unless they are mosaics. More data is needed in CIOF women before the final consensus of recombinant growth hormone (rGH) and oxandrolone can be reached. It is important to note that treatment with rGH has been restricted to study protocols, and only the treatment of growth hormone deficiency is FDA approved. Currently it appears prudent to discuss treatment options with patients having hypergonadotropic hypogonadism with respect to sexual development, reproductive potential, growth, and the prevention of complications such as osteoporosis and heart disease. It is the opinion of this author that if patients do desire to use rGH and oxandrolone, that they be treated by physicians directly involved in research protocols or after discussion with investigators who have experience in these treatment protocols. The induction of secondary sexual characteristics may be started after the completion of treatment for growth, which may be up to 3-5 years. If the woman does not desire therapy for growth, it appears reasonable to begin hormone replacement at ages 9-11, or at the time of diagnosis, if the individual is older. Likewise, males may begin testosterone treatment beginning at about ages 10-12. Support, discussion about potential complications of the disease and the replacement medication, and psychologic considerations must be considered for the complete management in individuals with hypogonadism.

KW - Hypergonadotropic hypogonadism

KW - Ovarian failure

KW - Sexual development

UR - http://www.scopus.com/inward/record.url?scp=0028630713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028630713&partnerID=8YFLogxK

U2 - 10.1016/S0932-8610(19)80172-X

DO - 10.1016/S0932-8610(19)80172-X

M3 - Review article

AN - SCOPUS:0028630713

VL - 7

SP - 183

EP - 193

JO - Journal of Pediatric and Adolescent Gynecology

JF - Journal of Pediatric and Adolescent Gynecology

SN - 1083-3188

IS - 4

ER -